Table 1.

Demographic, clinical, laboratory data, medication profiles, clinical course and final outcome in Han Chinese with the AS-associated UC manifestation.

No.	Age Sex	DP (yr)	Involved joints	Medication before the onset of IBD*	BASDAI/ESR/CRP† at the onset of IBD	IBD clinical/laboratory manifestation	IBD medications	Clinical course	Final outcome
1	28 M	10	SI, spine, hip, shoulder, knee	MTX, NSAIDs, SAZ	8.3/55/31.5	Bloody diarrhea/anemia	Corticosteroids/mSAZ with relapse	Recurrent IBD	Death at 38  y/o due to infection
2	46 M	20	SI, spine, hip	NSAIDs, SAZ	7.5/50/26.9	Bloody diarrhea, fever/ anemia	Corticosteroids/mSAZ with relapse	Recurrent IBD	Death at 50  y/o due to infection
3	35 M	15	SI, spine, hip	NSAIDs, SAZ	8.8/80/60.2	Bloody diarrhea, fever/ anemia	Corticosteroids/mSAZ with relapse, ADA 40 mg every 2 to 4 week	No relapse for 6.7 years after the ADA usage	Alive with lowarthritis activity (BASDAI 2~3)
4	45 F	25	SI, spine, hip, shoulder	MTX, NSAIDs, SAZ	8.1/35/18.8	Bloody diarrhea/anemia	Corticosteroids/SAZ with relapse, ADA 40  mg every 2 to 4 week	No relapse for 5.2 years after the ADA usage	Alive with low arthritis activity (BASDAI 2~3)

ADA: adalimumab, DP: disease period, F: female, IBD: inflammatory bowel disease, M: male, mSAZ: messalazopyrin,

MTX: methotrexate, No.: number, NSAIDs: nonsteroidal anti-inflammatory drugs, SAZ: salazopyrin, SI: sacroiliac,

UC: ulcerative colitis, yr: year

*MTX 10 to 15 mg per week, SAZ 2 to 3 g/ day, NSAIDs replaced with celecoxib after the development of IBD

^†ESR normal value ≤ 15 mm/hr, CRP normal value ≤ 8 mg/L

^#High dosages of corticosteroids (1~2 mg/kg/day prednisolone equivalent doses) during active colitis, mSAZ 2 to 3 g/day.